Active Ingredient History
The ALOIN A (barbaloin) is considered to be the most specific secondary phytoconstituent in Aloe species, widely distributed throughout the world. Barbaloin has been found to have a strong inhibitory effect on histamine release from mast cells. Orally administered barbaloin is poorly absorbed but is metabolized by intestinal microflora to aloe emodin, which is readily absorbed. Barbaloin is the main medicinal constituent of aloe vera, which has anti-inflammatory activity. Moreover, it has strong anti-oxidant and anti-tumor properties. For example, barbaloin inhibited the proliferation and metastasis of non-small cell lung carcinoma cells in vivo and in vitro. Barbaloin demonstrated a cardioprotective potential: barbaloin pretreatment attenuates myocardial ischemia-reperfusion injury. Plus, it might be used as an antiarrhythmic drug. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (Phase 1)
Anthrax (Phase 2)
Brain Ischemia (Phase 3)
Caliciviridae Infections (Phase 1)
Campylobacter Infections (Phase 1)
Cerebrospinal Fluid Leak (Phase 3)
Chikungunya Fever (Phase 2)
Chikungunya virus (Phase 3)
Clostridium Infections (Phase 2)
Conjunctivitis (Phase 1)
Constipation (Phase 3)
COVID-19 (Phase 4)
Dengue (Phase 1)
Dermatitis, Atopic (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetic Foot (Phase 4)
Diphtheria (Phase 2)
Diphtheria Toxoid (Phase 2)
Dyspepsia (Phase 4)
Dysuria (Phase 3)
Emergencies (Phase 4)
Enterovirus Infections (Phase 2)
Esophagitis (Phase 3)
Flavivirus Infections (Phase 1)
Gastroesophageal Reflux (Phase 4)
Head and Neck Neoplasms (Phase 1/Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Hemorrhoids (Phase 3)
HIV (Phase 1)
HIV Infections (Phase 1/Phase 2)
Hookworm Infections (Phase 2)
Hypercholesterolemia (Phase 1)
Infections (Phase 1)
Influenza A Virus, H5N1 Subtype (Phase 1)
Influenza A Virus, H7N9 Subtype (Phase 2)
Influenza, Human (Phase 1/Phase 2)
Leishmaniasis, Cutaneous (Phase 1)
Malaria (Phase 1/Phase 2)
Malaria, Falciparum (Phase 1)
Meningococcal Infections (Phase 1)
Multiple System Atrophy (Phase 1)
Neurodegenerative Diseases (Phase 1)
Norovirus (Phase 1)
Pain (Phase 4)
Papillomaviridae (Phase 1/Phase 2)
Parkinson Disease (Phase 1)
Plague (Phase 1)
Pneumococcal Infections (Phase 2)
Pneumonia, Pneumococcal (Phase 2)
Prostatic Neoplasms (Phase 1)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Pulmonary Emphysema (Phase 2)
Respiratory Syncytial Virus Infections (Phase 1)
Respiratory Tract Diseases (Phase 2)
Respiratory Tract Infections (Phase 2)
Rheumatic Fever (Phase 1)
Rhinitis, Allergic (Phase 1)
RNA Virus Infections (Phase 2)
Schistosoma mansoni (Phase 1/Phase 2)
Schistosomiasis (Phase 1/Phase 2)
Severe Acute Respiratory Syndrome (Phase 1)
Stomatitis (Phase 4)
Streptococcal Infections (Phase 1)
Subarachnoid Hemorrhage (Phase 3)
Tetanus (Phase 2)
Tobacco Use Disorder (Phase 2)
Vasculitis (Phase 1)
Vasospasm, Intracranial (Phase 3)
Virus Diseases (Phase 2)
Whooping Cough (Phase 2)
Zika Virus (Phase 1)
Zika Virus Infection (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
